Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate

References

• Daubney R, Hudson JR. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep cattle and man from East Africa. J Path Bact. 1931;34:545–579.
   Google Scholar
• Smithburn KC, Haddow AJ, Gillett JD. Rift Valley fever; isolation of the virus from wild mosquitoes. Br J Exp Pathol. 1948;29(2):107–121.
   PubMedGoogle Scholar
• Swanepoel R, Coetzer JAW. Rift Valley fever. In: Coetzer JAW, Tustin RC, editors. Infectious diseases of livestock with special reference to southern Africa. Vol. 2004. 2nd ed. Cape Town (South Africa): Oxford University Press; 2004. p. 1037–1070.
   Google Scholar
• Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses. 2011;3(5):493–519.
   PubMed Web of Science ®Google Scholar
• Peters CJ, Meegan JM. Rift Valley fever. In: Beran GW, Steele JH, editors. Handbook series of zoonoses, section b: viral zoonoses. Vol. 1. Boca Raton (FL): CRC Press; 1981. p. 403–420.
   Google Scholar
• Balkhy HH, Memish ZA. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int J Antimicrob Agents. 2003;21(2):153–157.
   PubMed Web of Science ®Google Scholar
• Nanyingi MO, Munyua P, Kiama SG, et al. A systematic review of Rift Valley fever epidemiology 1931-2014. Infect Ecol Epidemiol. 2015;5:28024.
   PubMedGoogle Scholar
• Liu W, Sun FJ, Tong YG, et al. Rift Valley fever virus imported into China from Angola. Lancet Infect Dis. 2016;16(11):1226.
   PubMed Web of Science ®Google Scholar
• Pepin M, Bouloy M, Bird BH, et al. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res. 2010;41(6):61.
   PubMed Web of Science ®Google Scholar
• Smithburn KC. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol. 1949;30(1):1–16.
   PubMedGoogle Scholar
• Botros B, Omar A, Elian K, et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol. 2006;78(6):787–791.
   PubMed Web of Science ®Google Scholar
• Grobbelaar AA, Weyer J, Leman PA, et al. Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis. 2011;17(12):2270–2276.
   PubMed Web of Science ®Google Scholar
• Yedloutschnig RJ, Dardiri AH, Mebus CA, et al. Abortion in vaccinated sheep and cattle after challenge with Rift Valley fever virus. Vet Rec. 1981;109(17):383–384.
   PubMed Web of Science ®Google Scholar
• Kortekaas J. One health approach to Rift Valley fever vaccine development. Antiviral Res. 2014;106:24–32.
   PubMed Web of Science ®Google Scholar
• FAO. 2015. The last hurdles towards Rift Valley fever control. Report on the Ad hoc workshop on the current state of Rift Valley fever vaccine and diagnostics development – Rome, 5-7 March 2014. FAO Animal Production and Health Report No. 9. Rome (Italy).
   Google Scholar
• Indran SV, Ikegami T. Novel approaches to develop Rift Valley fever vaccines. Front Cell Infect Microbiol. 2012;2:131.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Makino S. Rift Valley fever vaccines. Vaccine. 2009;27 Suppl 4:D69–D72.
   PubMed Web of Science ®Google Scholar
• Caplen H, Peters CJ, Bishop DH. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol. 1985;66(Pt 10):2271–2277.
   PubMed Web of Science ®Google Scholar
• Lokugamage N, Freiberg AN, Morrill JC, et al. Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains. J Virol. 2012;86:13566–13575.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Jennings GB, Caplen H, et al. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res. 1987;48(7):1042–1047.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Carpenter L, Taylor D, et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine. 1991;9(1):35–41.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Mebus CA, Peters CJ. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res. 1997;58(10):1104–1109.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Mebus CA, Peters CJ. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res. 1997;58(10):1110–1114.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Laughlin RC, Lokugamage N, et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine. 2013;31:559–565.
   PubMed Web of Science ®Google Scholar
• Hubbard KA, Baskerville A, Stephenson JR. Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever. Am J Vet Res. 1991;52(1):50–55.
   PubMed Web of Science ®Google Scholar
• Baskerville A, Hubbard KA, Stephenson JR. Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine. Res Vet Sci. 1992;52(3):307–311.
   PubMed Web of Science ®Google Scholar
• Miller MM, Bennett KE, Drolet BS, et al. Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep. Clin Vaccine Immunol. 2015;22(8):930–937.
   PubMed Web of Science ®Google Scholar
• Lihoradova O, Kalveram B, Indran SV, et al. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. J Virol. 2012;86(14):7650–7661.
   PubMed Web of Science ®Google Scholar
• Lihoradova OA, Indran SV, Kalveram B, et al. Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or Sandfly fever Sicilian virus. Plos Negl Trop Dis. 2013;7(4):e2181.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Peters CJ. Mucosal immunization of rhesus macaques with Rift Valley fever MP-12 vaccine. J Infect Dis. 2011;204(4):617–625.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Peters CJ. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus. J Infect Dis. 2011;204(2):229–236.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Peters CJ. Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine. 2003;21(21–22):2994–3002.
   PubMed Web of Science ®Google Scholar
• Pittman PR, McClain D, Quinn X, et al. Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans. Vaccine. 2016;34(4):424–429.
   PubMed Web of Science ®Google Scholar
• Pittman PR, Norris SL, Brown ES, et al. Rift Valley fever MP-12 vaccine phase 2 clinical trial: safety, immunogenicity, and genetic characterization of virus isolates. Vaccine. 2016;34(4):523–530.
   PubMed Web of Science ®Google Scholar
• Hills RE. Issuance of a conditional license for Rift Valley fever vaccine, modified live virus. Notice no. 13-12. Ames (IA): Center for Veterinary Biologics; 2013.
   Google Scholar
• Environmental assessment – Rift Valley fever vaccine, modified live virus (unlicensed in Canada and USA), the Canadian Centre for Veterinary Biologics (CCVB) of the Canadian Food Inspection Agency (CFIA). 2013. Available from: http://www.inspection.gc.ca/animals/veterinary-biologics/licensed-products/environmental-assessments/rift-valley-fever-vaccine/eng/1393256796335/1393256857602.
   Google Scholar
• Wilson WC, Bawa B, Drolet BS, et al. Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination. Vet Microbiol. 2014;172(1–2):44–50.
   PubMed Web of Science ®Google Scholar
• Rissmann M, Ulrich R, Schroder C, et al. Vaccination of alpacas against Rift Valley fever virus: safety, immunogenicity and pathogenicity of MP-12 vaccine. Vaccine. 2017;35(4):655–662.
   PubMed Web of Science ®Google Scholar
• Hunter P, Erasmus BJ, Vorster JH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res. 2002;69(1):95–98.
   PubMed Web of Science ®Google Scholar
• Antonis AF, Kortekaas J, Kant J, et al. Vertical transmission of rift valley fever virus without detectable maternal viremia. Vector Borne Zoonotic Dis. 13(8):601–606.
   PubMed Web of Science ®Google Scholar
• Coetzer JA, Barnard BJ. Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and Rift Valley fever viruses as aetiological agents. Onderstepoort J Vet Res. 1977;44(2):119–126.
   PubMedGoogle Scholar
• Kamal SA. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J. 2009;6:94.
   PubMed Web of Science ®Google Scholar
• Makoschey B, Van Kilsdonk E, Hubers WR, et al. Rift Valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths. Plos Negl Trop Dis. 2016;10(3):e0004550.
   PubMed Web of Science ®Google Scholar
• Lo MM, Mbao V, Sierra P, et al. Safety and immunogenicity of Onderstepoort Biological Products’ Rift Valley fever Clone 13 vaccine in sheep and goats under field conditions in Senegal. Onderstepoort J Vet Res. 2015;82(1):857.
   PubMed Web of Science ®Google Scholar
• Njenga MK, Njagi L, Thumbi SM, et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. Plos Negl Trop Dis. 2015;9(3):e0003550.
   PubMed Web of Science ®Google Scholar
• Pittman PR, Liu CT, Cannon TL, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine. 1999;18(1–2):181–189.
   PubMed Web of Science ®Google Scholar
• Rusnak JM, Gibbs P, Boudreau E, et al. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine. 2011;29(17):3222–3229.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services FDA. Guidance for industory: toxicology grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. DHHS/FDA, Washington, DC. 2007. Available from: https://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074775.htm.
   Google Scholar
• U.S. Department of Health and Human Services FDA. Approval of biological products when human efficacy studies are not ethical or feasible. DHHS/FDA, Washington, DC. Title 21 Code of Federal Regulations, Subpart H, Section 601.90.
   Google Scholar
• U.S. Department of Health and Human Services FDA. Approval based on evidence of effectiveness from studies in animals. DHHS/FDA, Washington, DC. Title 21 Code of Federal Regulations, Subpart I, Section 314.610.
   Google Scholar
• Snoy PJ. Establishing efficacy of human products using animals: the US Food and Drug Administration’s “animal rule”. Vet Pathol. 2010;47(5):774–778.
   PubMed Web of Science ®Google Scholar
• Turell MJ, Rossi CA. Potential for mosquito transmission of attenuated strains of Rift Valley fever virus. Am J Trop Med Hyg. 1991;44(3):278–282.
   PubMed Web of Science ®Google Scholar
• Turell MJ, Saluzzo JF, Tammariello RF, et al. Generation and transmission of Rift Valley fever viral reassortants by the mosquito Culex pipiens. J Gen Virol. 1990;71(Pt 10):2307–2312.
   PubMed Web of Science ®Google Scholar
• Briese T, Bird B, Kapoor V, et al. Batai and Ngari viruses: M segment reassortment and association with severe febrile disease outbreaks in East Africa. J Virol. 2006;80(11):5627–5630.
   PubMed Web of Science ®Google Scholar
• Gerrard SR, Li L, Barrett AD, et al. Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol. 2004;78(16):8922–8926.
   PubMed Web of Science ®Google Scholar
• Briese T, Kapoor V, Lipkin WI. Natural M-segment reassortment in Potosi and main drain viruses: implications for the evolution of orthobunyaviruses. Arch Virol. 2007;152(12):2237–2247.
   PubMed Web of Science ®Google Scholar
• Berthet N, Nakoune E, Gessain A, et al. Complete genome characterization of the arumowot virus (unclassified Phlebovirus) isolated from Turdus libonyanus birds in the Central African Republic. Vector Borne Zoonotic Dis. 2016;16(2):139–143.
   PubMed Web of Science ®Google Scholar
• Tesh RB. The genus Phlebovirus and its vectors. Annu Rev Entomol. 1988;33:169–181.
   PubMed Web of Science ®Google Scholar
• Traore-Lamizana M, Fontenille D, Diallo M, et al. Arbovirus surveillance from 1990 to 1995 in the Barkedji area (Ferlo) of Senegal, a possible natural focus of Rift Valley fever virus. J Med Entomol. 2001;38(4):480–492.
   PubMed Web of Science ®Google Scholar
• Kemp GE, Causey OR, Setzer HW, et al. Isolation of viruses from wild mammals in West Africa, 1966-1970. J Wildl Dis. 1974;10(3):279–293.
   PubMedGoogle Scholar
• Ikegami T, Hill TE, Smith JK, et al. Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L Segments. J Virol. 2015;89(14):7262–7276.
   PubMed Web of Science ®Google Scholar
• Billecocq A, Gauliard N, Le May N, et al. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology. 2008;378(2):377–384.
   PubMed Web of Science ®Google Scholar
• Saluzzo JF, Smith JF. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine. 1990;8(4):369–375.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Ikegami T. Temperature-sensitive mutations for live-attenuated Rift Valley fever vaccines: implications from other RNA viruses. Front Microbiol. 2015;6:787.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Lokugamage N, Ikegami T. The L-, M- and S-segments of Rift Valley fever virus MP-12 vaccine independently contribute to a temperature-sensitive phenotype. J Virol. 2016;90(7):3735–37644.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Won S, Peters CJ, et al. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol. 2006;80(6):2933–2940.
   PubMed Web of Science ®Google Scholar
• Gerrard SR, Bird BH, Albariño CG, et al. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology. 2007;359(2):459–465.
   PubMed Web of Science ®Google Scholar
• Habjan M, Penski N, Spiegel M, et al. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J Gen Virol. 2008;89(Pt 9):2157–2166.
   PubMed Web of Science ®Google Scholar
• Won S, Ikegami T, Peters CJ, et al. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol. 2007;81(24):13335–13345.
   PubMed Web of Science ®Google Scholar
• Crabtree MB, Kent Crockett RJ, Bird BH, et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. Plos Negl Trop Dis. 2012;6(5):e1639.
   PubMed Web of Science ®Google Scholar
• Kading RC, Crabtree MB, Bird BH, et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. Plos Negl Trop Dis. 2014;8(2):e2670.
   PubMed Web of Science ®Google Scholar
• Kreher F, Tamietti C, Gommet C, et al. The Rift Valley fever accessory proteins NSm and P78/NSm-Gn are determinants of virus propagation in vertebrate and invertebrate hosts. Emerg Microbe Infect. 2014;3:e71.
   PubMed Web of Science ®Google Scholar
• Bird BH, Maartens LH, Campbell S, et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol. 2011;85(24):12901–12909.
   PubMed Web of Science ®Google Scholar
• Morrill JC, Laughlin RC, Lokugamage N, et al. Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Vaccine. 2013;31(43):4988–4994.
   PubMed Web of Science ®Google Scholar
• Weingartl HM, Nfon CK, Zhang S, et al. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep. Vaccine. 2014;32(20):2345–2349.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Slack OA, Lokugamage N, et al. Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR. Virulence. 2016;7(8):1–11.
   Web of Science ®Google Scholar
• Bird BH, Albariño CG, Nichol ST. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology. 2007;362(1):10–15.
   PubMed Web of Science ®Google Scholar
• Lihoradova O, Ikegami T. Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever. Expert Rev Vaccines. 2012;11(11):1283–1285.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Narayanan K, Won S, et al. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. Plos Pathog. 2009;5(2):e1000287.
   PubMed Web of Science ®Google Scholar
• Li S, Koromilas AE. Dominant negative function by an alternatively spliced form of the interferon-inducible protein kinase PKR. J Biol Chem. 2001;276(17):13881–13890.
   PubMed Web of Science ®Google Scholar
• Indran SV, Lihoradova OA, Phoenix I, et al. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice. J Gen Virol. 2013;94(Pt 7):1441–1450.
   PubMed Web of Science ®Google Scholar
• Alhaj M. Safety and efficacy profile of commercial veterinary vaccines against Rift Valley fever: a review study. J Immunol Res. 2016;2016:1–7.
   Web of Science ®Google Scholar
• Ahmed Kamal S. Observations on rift valley fever virus and vaccines in Egypt. Virol J. 2011;8:532.
   PubMed Web of Science ®Google Scholar
• Barnard BJ, Botha MJ. An inactivated rift valley fever vaccine. J S Afr Vet Assoc. 1977;48(1):45–48.
   PubMed Web of Science ®Google Scholar
• Davies FG, Martin V. Prevention and control of Rift Valley fever. In: Recognizing Rift Valley fever. FAO Animal Health Manual. Rome (Italy), FAO; 2003. p. 33–38.
   Google Scholar
• Métras R, Baguelin M, Edmunds WJ, et al. Transmission potential of Rift Valley fever virus over the course of the 2010 epidemic in South Africa. Emerg Infect Dis. 2013;19(6):916–924.
   PubMed Web of Science ®Google Scholar
• Al-Afaleq AI, Hussein MF. The status of Rift Valley fever in animals in Saudi Arabia: a mini review. Vector Borne Zoonotic Dis. 2011;11(12):1513–1520.
   PubMed Web of Science ®Google Scholar
• Kortekaas J, Oreshkova N, Van Keulen L, et al. Comparative efficacy of two next-generation Rift Valley fever vaccines. Vaccine. 2014;32(39):4901–4908.
   PubMed Web of Science ®Google Scholar
• Kortekaas J, Oreshkova N, Cobos-Jimenez V, et al. Creation of a non-spreading Rift Valley fever virus. J Virol. 2011;85:12622–12630.
   PubMed Web of Science ®Google Scholar
• Warimwe GM, Gesharisha J, Carr BV, et al. Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever. Sci Rep. 2016;6:20617.
   PubMed Web of Science ®Google Scholar
• Warimwe GM, Lorenzo G, Lopez-Gil E, et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J. 2013;10:349.
   PubMed Web of Science ®Google Scholar
• Dulal P, Wright D, Ashfield R, et al. Potency of a thermostabilised chimpanzee adenovirus Rift Valley fever vaccine in cattle. Vaccine. 2016;34(20):2296–2298.
   PubMed Web of Science ®Google Scholar
• Faburay B, Lebedev M, McVey DS, et al. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis. 2014;14(10):746–756.
   PubMed Web of Science ®Google Scholar
• Faburay B, Wilson WC, Gaudreault NN, et al. A recombinant Rift Valley fever virus glycoprotein subunit vaccine confers full protection against Rift Valley fever challenge in sheep. Sci Rep. 2016;6:27719.
   PubMed Web of Science ®Google Scholar
• Faburay B, Wilson W, McVey DS, et al. Rift valley Fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep. Vector Borne Zoonotic Dis. 2013;13(9):619–629.
   PubMed Web of Science ®Google Scholar
• Bird BH, Nichol ST. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol. 2012;2(3):315–323.
   PubMed Web of Science ®Google Scholar
• Gowen BB, Westover JB, Sefing EJ, et al. MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters. Front Microbiol. 2015;6:651.
   PubMed Web of Science ®Google Scholar
• Gowen BB, Bailey KW, Scharton D, et al. Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge. Antiviral Res. 2013;98(2):135–143.
   PubMed Web of Science ®Google Scholar